Charged polylactide co-glycolide microparticles as antigen delivery systems

Expert Opinion on Biological Therapy

Volumn 4, Issue 4, 2004, Pages 483-491

  Singh, Manmohan ^a   Kazzaz, Jina ^a   Ugozzoli, Mildred ^a   Chesko, James ^a   O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adjuvants; DNA vaccines; Microparticles; Polylactide co glycolide polymer; Vaccine delivery systems

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANIONIC SURFACTANT; ANTIGEN; CATIONIC SURFACTANT; CETRIMIDE; CHOLERA VACCINE; DIPHTHERIA TOXOID; DNA VACCINE; DOCUSATE SODIUM; FREUND ADJUVANT; GAG PROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIVE VACCINE; MURAMYL DIPEPTIDE; NAKED DNA; NANOPARTICLE; OLIGONUCLEOTIDE; OVALBUMIN; PLASMID DNA; POLIOMYELITIS VACCINE; POLYGLACTIN; POLYMER; PROTEIN P55; QS 21; RECOMBINANT ANTIGEN; SALMONELLOSIS VACCINE; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS VACCINE; TETANUS TOXOID;

ADSORPTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; CELL POPULATION; CELLULAR IMMUNITY; CONTROLLED DRUG RELEASE; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; ELECTRICITY; EMULSION; ENZYME LINKED IMMUNOSPOT ASSAY; EVAPORATION; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTERMETHOD COMPARISON; MICROENCAPSULATION; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; NONHUMAN; PARTICLE SIZE; REVIEW; SURFACE CHARGE; T LYMPHOCYTE; VACCINE PRODUCTION;

ANIMALS; ANTIGENS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; MICROSPHERES; POLYGLYCOLIC ACID; POLYMERS; VACCINES, DNA;

NEISSERIA; NEISSERIA MENINGITIDIS; STAPHYLOCOCCUS;

EID: 1842784818     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.4.483     Document Type: Review

References (55)

1. O'HAGAN DT: Microparticles as oral vaccines. In: Novel Delivery Systems for Oral Vaccines. O'Hagan DT (Ed.) CRC Press, Inc., Boca Raton, FL (1994):175-205.
2. KOVACSOVICS-BANKOWSKI M, CLARK K, BENACERRAF B, ROCK KL: Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad Sci. USA (1993) 90:4942-4946.
3. OKADA H, TOGUCHI H: Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12:1-99.
4. PUTNEY SD, BURKE PA: Improving protein therapeutics with sustained-release formulations [published erratum appears in Nat. Bietechnol. 1998 May;16(5):478]. Nat. Biotechnol. (1998) 16:153-157.
5. PUTNEY SD, BURKE PA: Improving protein therapeutics with sustained-release formulations [published erratum appears in Nat. Bietechnol. 1998 May;16(5):478]. Nat. Biotechnol. (1998) 16:153-157.
6. ELDRIDGE JH, STAAS JK, MEULSROEK JA, TICE TR, GILLEY RM: Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immum. (1991) 59:2978-2986.
7. O'HAGAN DT, RAHMAN D, MCGEE JP et al.: Biodegradable microparticles as controlled release antigen delivery systems. Immunology (1991) 73:239-242.
8. SINGH M, SINGH A, TALWAR GP: Controlled delivery of diphtheria toxoid using biodegradable poly(D,L-lactide) microcapsules. Pharm. Res. (1991) 8:958-961.
9. O'HAGAN DT, JEFFERY H, ROBERTS MJ, MCGEE JP, DAVIS SS: Controlled release microparticles for vaccine development. Vaccine (1991) 9:768-771.
10. MALOY KJ, DONACHIE AM, O'HAGAN DT, MOWAT AM: Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology (1994) 81:661-667.
11. MOORE A, MCGUIRK P, ADAMS S et al.: Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine (1995) 13:1741-1749.
12. NIXON DF, HIOE C, CHEN PD et al.: Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine (1996) 14:1523-1530.
13. KANKE M, SNIECINSKI I, DELUCA PP: Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J. Parenter. Sci. Technol. (1983) 37:210-217.
14. TABATA Y, IKADA Y: Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycotic acid homo- and copolymers. J. Biomed. Mater. Res. (1988) 22:837-858.
15. TABATA Y, IKADA Y: Phagocytosis of polymer microspheres by macrophages. Adv. Polymer Sci. (1990) 94:107-141.
16. RANDOLPH GJ, INABA K, ROBBIANI DF, STEINMAN RM, MULLER WA: Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity (1999) 11:753-761.
17. LUTSIAK ME, ROBINSON DR, COESTER C, KWON GS, SAMUEL J: Analysis of poly(D,L-latic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. (2002) 19:1480-1487.
18. NEWMAN KD, ELAMANCHILI P, KWON GS, SAMUEL J: Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. (2002) 60:480-486.
19. O'HAGAN DT, JEFFERY H, DAVIS SS: Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine (1993) 11:965-969.
20. O'HAGAN DT, UGOZZOLI M, BARACKMAN J et al.: Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine (2000) 18:1793-1801.
21. OTTEN G, SCHAEFER M, GREER C et al. Induction of broad and potent antihuman immunodeficiency virus immune responses in rhesus macques by priming with a DNA vaccine and boosting with protein adsorbed polylactide microparticles. J. Virol. (2003) 77:6087-6092.
22. KAZZAZ J, NEIDLEMAN J, SINGH M, OTT G, O'HAGAN DT: Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control Release (2000) 67:347-356.
23. SINGH M, KAZZAZ J, CHESKO J et al.: Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. (2004) 93:273-282.
24. JUNG T, KAMM W, BREITENBACH A et al.: Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. (2001) 18:352-360.
25. O'HAGAN DT, JEFFERY H, DAVIS SS: Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine (1993) 11:965-969.
26. SEDER RA, GURUNATHAN S: DNA vaccines-designer vaccines for the 21st century. N. Engl. J. Med. (1999) 341:277-278.
27. WANG R, DOOLAN DL, LE TP et al.: Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 282:476-480.
28. CALAROTA S, BRATT G, NORDLUND S et al.: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet (1998) 351:1320-1325.
29. SCHNEIDER J, GILBERT SC, BLANCHARD TJ et al.: Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. (1998) 4:397-402.
30. SULLIVAN NJ, SANCHEZ A, ROLLIN PE, YANG ZY, NABEL GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 408:605-609.
31. AMARA RP, VILLINGER F, ALTMAN JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292:69-74.
32. HEDLEY ML, CURLEY J, URBAN R: Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. (1998) 4:365-368.
33. WALTER E, MOELLING K, PAVLOVIC J, MERKLE HP: Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. (1999) 61:361-374.
34. ANDO S, PUTNAM D, PACK DW, LANGER R: PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. (1999) 88:126-130.
35. TINSLEY-BOWN AM, FRETWELL R, DOWSETT AB, DAVIS SL, FARRAR GH: Formulation of poly(D,L-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J. Control. Release (2000) 66:229-241.
36. SINGH M, BRIONES M, OTT G, O'HAGAN D: Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA (2000) 97:811-816.
37. BRIONES M, SINGH M, UGOZZOLI M et al.: The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. (2001) 18:709-711.
38. O'HAGAN D, SINGH M, UGOZZOLI M et al.: Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. (2001) 75:9037-9043.
39. DENIS-MIZE KS, DUPUIS M, MACKICHAN ML et al.: Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. (2000) 7:2105-2112.
40. OTT G, SINGH M, KAZZAZ J et al.: A cationic sub-micron emulsion (MF59/ DOTAP) is an effective delivery system for DNA vaccines. J. Control. Release (2002) 79:1-5.
41. SINGH M, OTT G, KAZZAZ J et al.: Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. (2001) 18:1476-1479.
42. TABATA Y, IKADA Y: Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. (1987) 39:698-704.
43. PURI N, SINKO PJ: Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. J. Control. Release (2000) 69:69-80.
44. CLELAND JL, BARRON L, DAUGHERTY A et al.: Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. J. Pharm. Sci. (1997) 85:1350-1357.
45. O'HAGAN DT: HIV and mucosal immunity. Lancet (1991) 337:1289.
46. O'HAGAN DT, SINGH M, KAZZAZ J et al.: Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine (2002) 20:3389-3398.
47. LEVINE MM, DOUGAN G: Optimism over vaccines administered via mucosal surfaces. Lancet (1998) 351:1375-1376.
48. O'HAGAN D: Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. (1998) 34:305-320.
49. VAJDY M, O'HAGAN DT: Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. (2001) 51:127-141.
50. SINGH M, VAJDY M, GARDNER J, BRIONES M, O'HAGAN D: Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity Vaccine (2002) 20:594-602.
51. PARK TG, LU W, CROTTS G: Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D,L-lactic acid-co-glycolic acid) microspheres. J. Control. Release (1995) 33:211.
52. SHENDEROVA A, BURKE TG, SCHWENDEMAN SP: The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm. Res. (1999) 16:241-248.
53. VAN DE WEERT M, HENNINK WE, JISKOOT W: Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. (2000) 17:1159-1167.
54. JOHNSON RE, LANASKI LA, GUPTA V et al.: Stability of atriopeptin III in poly (lactide-co-glycolide) microparticles. J. Control. Release (1991) 17:61.
55. DENIS-MIZE KS, DUPUIS M, SINGH M et al.: Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell. Immunol. (2003) 225:12-20.